Cargando...
The surge in biosimilars: considerations for effective pharmacovigilance and EU regulation
The development of biosimilars is growing rapidly, especially in Europe. They are a cost-effective alternative to original biological medicines and can help improve patient access to these therapies. The European Medicines Agency (EMA) has been the first to issue scientific guidelines related to reg...
Guardado en:
| Publicado en: | Ther Adv Drug Saf |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166315/ https://ncbi.nlm.nih.gov/pubmed/30283628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098618790442 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|